Chavda Vivek P, Patel Aayushi B, Vora Lalitkumar K, Apostolopoulos Vasso, Uhal Bruce D
Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad, India.
Pharmacy Section, LM College of Pharmacy, Ahmedabad, India.
Expert Rev Vaccines. 2022 Oct;21(10):1395-1403. doi: 10.1080/14760584.2022.2110076. Epub 2022 Aug 9.
A correlation between new coronaviruses and host immunity, as well as the role of defective immune function in host response, would be extremely helpful in understanding coronavirus disease (COVID-19) pathogenicity, and a coherent structure of treatments and vaccines. As existing vaccines may be inadequate for new viral variants emerging in various regions of the world, it is a vital requirement for fresh and effective therapeutic alternatives.
Immunotherapy may give a viable protective option for COVID-19, a disease that is currently a big burden on global health and economic systems. Herein, we have outlined three dendritic cell (DC)-based vaccines for COVID-19 which are in human clinical trials and have shown encouraging outcomes.
With existing knowledge of the virus, and the nature of DC, DC-based vaccines may be proven to be effective in inducing long-lasting protective immunity, especially T cell responses.
新型冠状病毒与宿主免疫之间的关联，以及免疫功能缺陷在宿主反应中的作用，对于理解冠状病毒病（COVID-19）的致病性以及治疗和疫苗的连贯结构极为有帮助。由于现有疫苗可能不足以应对在世界各个地区出现的新病毒变体，因此迫切需要新的有效治疗选择。
免疫疗法可能为COVID-19提供一种可行的保护选择，该疾病目前给全球健康和经济系统带来巨大负担。在此，我们概述了三种用于COVID-19的基于树突状细胞（DC）的疫苗，它们正在进行人体临床试验，并已显示出令人鼓舞的结果。
基于现有对该病毒的了解以及DC的性质，基于DC的疫苗可能被证明在诱导持久的保护性免疫方面有效，尤其是T细胞反应。
